REG - Cizzle Biotechnology - Change of Registered Office

Cizzle Biotechnology HoldingsAnnouncement

27/10/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa9588Ea&default-theme=true

RNS Number : 9588E  Cizzle Biotechnology Holdings PLC  27 October 2025

27 October 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Change of Registered Office

 

Cizzle Biotechnology, the UK based diagnostics developer of early cancer
tests, confirms that it has changed its registered office and UK head office
from 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, to c/o Ampa Holdings
LLP, Level 19, The Shard, 32 London Bridge Street, London, SE1 9SG effective
immediately.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                             +44(0) 20 3328 5656
 John Depasquale/Piers Shimwell (Corporate Finance)
 Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited          +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Staton

 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care. Cizzle was admitted
to the Standard segment of the main market of the London Stock Exchange in May
2021.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CROFZMZGMNGGKZM



            Copyright 2019 Regulatory News Service, all rights reserved